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Small molecule inhibitorsNuclear import is a critical step in the life cycle of HIV-1. During the early (preintegration) stages of infection,
HIV-1 has to transport its preintegration complex into the nucleus for integration into the host cell
chromatin, while at the later (postintegration) stages viral regulatory proteins Tat and Rev need to get into
the nucleus to stimulate transcription and regulate splicing and nuclear export of subgenomic and genomic
RNAs. Given such important role of nuclear import in HIV-1 life cycle, this step presents an attractive target
for antiviral therapeutic intervention. In this review, we describe the current state of our understanding of
the interactions regulating nuclear import of the HIV-1 preintegration complex and describe current
approaches to inhibit it. This article is part of a Special Issue entitled: Regulation of Signaling and Cellular
Fate through Modulation of Nuclear Protein Import.ation of Signaling and Cellular
DC 20037, USA.
y).
ll rights reserved.© 2010 Elsevier B.V. All rights reserved.1. Introduction
Viruses are intracellular parasites that commandeer cellular
processes, such as nuclear import and export machineries, to perform
virus-speciﬁc functions. For this purpose, many viral proteins and
nucleoprotein complexes shuttle between the nuclear and cytoplas-
mic compartments, and this process is especially critical for viruses
with a distinct replication step occurring in the nucleus. Among many
different families of these viruses, retroviruses, and lentiviruses in
particular, are of major interest both because of their clinical
importance (HIV-1 is the most notable lentiviral pathogenic agent
[1]) and their potential relevance as vectors for gene therapy [2].
While replication in the host cell's nucleus provides clear beneﬁts for
the virus, such as ready access to cellular transcription and splicing
apparatus, it imposes the barrier of the nuclear envelope that has to be
overcome. During the early (preintegration) stages of infection,
lentiviruses have to transport their genome from the site of penetration
to the nucleus and then through the nuclear membrane, while at the
later (postintegration) stages they need to import regulatory proteins
(Tat andRev in the caseofHIV-1) to stimulate transcription and regulate
splicing and nuclear export of subgenomic and genomic RNAs. Given
such important role that nuclear import plays in HIV-1 life cycle, it
presents an attractive target for antiviral therapeutic intervention. In
this review, we will describe the current state of our understanding ofthe interactions regulating nuclear import of the HIV-1 preintegration
complex (PIC) and HIV-1 proteins critical for viral replication, focusing
on potential targets for therapeutic interventions. In contrast to a recent
article by Zhan et al. [3] covering similar topics, we will attempt to
provide a critical analysis of the published data.
2. Nuclear import in the HIV-1 life cycle
The idea that nuclear import may play a special role in lentiviral
life cycle [4] was prompted by the ﬁnding that HIV-1 can infect
nondividing cells such as terminally differentiated macrophages [5,6].
This ability implied that HIV-1, unlike gammaretroviruses which
critically depend on nuclear envelope disassembly during mitosis for
nuclear entry [7], acquired the ability to pass through the intact
nuclear envelope. Because mitosis constitutes only a small part of the
cell cycle, the ability to enter nuclear compartment during the
interphase provides a huge beneﬁt to HIV-1 and may account for its
very high replication rate observed in HIV-infected patients [8,9].
Initially, it was presumed that HIV can get into the nucleus both
during the interphase (through the nuclear envelope) and during the
mitosis (bypassing the nuclear envelope), prompting the idea that
infection of dividing and nondividing cells by HIV occurs through
different pathways and thus should involve different mechanisms
[10]. However, a number of studies demonstrated that passage
through the nuclear envelope is a necessary step in HIV infection of
both dividing and nonproliferating cells [11–13], underscored by the
requirement of the nuclear import factors transportin-SR2 (TNPO3/
TRN-SR2) [14–16] and importin 7 [17] for infection of both cell types.
Such solution appears evolutionary sensible, as evolution usually
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ones, and it would be wasteful for a virus to preserve two replication
mechanisms (one for dividing and one for nondividing cells), when
one is so much superior to the other. The requirement of active
nuclear import for HIV infection of both dividing and nondividing cells
would imply that differences between these cell types in HIV
replication cannot be used for conclusions regarding the role of HIV
nuclear import in the viral life cycle [10,16,18]. Indeed, it is very
difﬁcult to make reliable conclusions from comparison of nondividing
cells growth arrested by potent antimitotic agents such as aphidicolin
to untreated controls. In addition, recent studies demonstrated
profound differences between dividing and nondividing, postmitotic
cells in the genesis of nuclear pore complexes (NPC), the multiprotein
assemblies that regulate exchange between the nucleoplasm and
cytoplasm. In dividing cells, NPCs disassemble during mitosis and
reassemble into the newly forming nuclei. In contrast, the renewal of
NPCs is absent in post-mitotic cells, and certain nucleoporins, such as
Nup107/160 complex, remain incorporated in the nuclear membrane
during the entire lifespan of a cell [19,20]. Lack of NPC turnover in
post-mitotic cells was associated with aging-related deterioration of
NPCs, a loss of the nuclear permeability barrier and the leaking of
cytoplasmic proteins into the nuclear compartment [21]. Such
functional changes may greatly affect the NPC activity during nuclear
import of viral PICs in nondividing cells.
Being cellular parasites, viruses hijack cellular machinery to
accomplish the necessary tasks in their replication. In the case of
nuclear import, this paradigm implies that the HIV-1 PIC and the viral
proteins needed in the nucleus (Tat and Rev) interact with the cellular
nuclear import machinery that normally mediates transport of certain
cellular proteins carrying speciﬁc nuclear localization signals (NLSs)
from the cytoplasm into the nucleus. This machinery involves a number
of nuclear transport proteins, importins, that bind and translocate NLS-
containingproteins through theNPC via a complex series of interactions
with NPC proteins nucleoporins (reviewed in Terry et al. [22]).
To use this machinery, the HIV-1 PIC and the viral proteins needed
in the nucleus (Tat and Rev) have to express NLSs that could be
recognized by importins. The questions concerning the nature of these
NLSs, the PIC proteins expressing them, and the importins involved in
translocation of the HIV-1 PIC remain the most controversial issue in
HIV research. HIV-1 PIC contains at least four karyophilic proteins of
both viral (MA, IN, Vpr) and host cell (LEDGF/p75) origin which have
been shown to interact with importins. Some of the existing
controversy comes from this unusually high number of potential
factors regulating HIV-1 nuclear import. Indeed, nuclear import of the
HIV-1 PIC cannot be completely suppressed by inactivation of NLSs in
any one, or even simultaneously in several, karyophilic proteins
within the PIC [23]. However, this ﬁnding can simply indicate that the
nuclear import of the HIV PIC results from a cumulative activity of
several karyophilic factors, or that different factors work in different
circumstances (e.g., different cell types, different activation condi-
tions, etc.). This would be a logical solution on the part of the virus to
maximize efﬁciency of its nuclear import. Consistent with this
interpretation, deletion or inactivation of known nuclear import
signals in the HIV-1 PIC leads to about a 4-log decrease in infectivity
[23]. Importantly, consistent with the critical role that nuclear import
plays in HIV-1 infection of dividing and nondividing cells, inactivation
of NLSs equally affected viral replication in both cell types [10].
Similar considerations concern importins. A number of these
nuclear import receptors, including importins α, β, 7, and TNPO3/
TRN-SR2 have been proposed as the key components of the HIV
nuclear import system in some reports, while other studies ques-
tioned their role. For example, using an in vitro model of nuclear
import, Fassati and colleagues identiﬁed importin 7 as the critical
component of PIC nuclear import and showed that RNAi-mediated
knockdown of Imp7 in macrophages inhibits viral nuclear import and
replication [24]. However, later study by Zielske and Stevenson [25]questioned this result by showing that knocking down Imp7 in
macrophages did not impair infection by HIV. Potential resolution of
this controversy may come from a recent report by Zaitseva et al. [17]
which suggested that inactivation of Imp7 affects kinetics of the PIC
nuclear import but not the ﬁnal accumulation of PICs in the nuclear
compartment. This scenario is similar to the situation with PIC NLSs
(see below), whose role might be to accelerate the process of PIC
nuclear import.
Interestingly, different lentiviruses appear to use alternative
nuclear import pathways to access the nucleus. For example, Imp7
is required for rapid nuclear import of HIV-1, but not for HIV-2 or SIV
[17]; TNPO3 is required for infection by HIV, SIV and BIV, but is
dispensable for FIV [26]; nuclear import of primate lentiviruses can be
inhibited by a fragment of cleavage and polyadenylation factor 6,
CPSF6-358, whereas FIV is insensitive to this factor [16]. The reason
for such diversity may lie in differences between the host species in
the level of immune cell activation associated with lentiviral infection
or the predominance of a certain target cell type. Indeed, hyperactiva-
tion of the immune system accompanies HIV infection of humans,
whereas no such prolonged activation is observed in sootymangabeys
or African green monkeys naturally infected with SIV [27]. The
primary target and reservoir of HIV infection are CD4+ T lymphocytes,
whereas maedi-visna virus targets preferentially macrophages and
does not infect T lymphocytes [28].
In addition to classical NLS-dependent pathways, HIV may use
alternative nuclear import pathways that appear to beNLS-independent.
One such pathway was identiﬁed by analyzing HeLa cytosolic fractions
for the ability to support nuclear import of puriﬁed HIV-1 PICs into
permeabilized nuclei. Surprisingly, the functional component of the
active fraction turned out to be enriched in tRNAmolecules, mostlywith
defective 3′ CCA ends [29]. Synthetic tRNAs also promoted nuclear
import of the PIC. Intriguingly, retrograde tRNA transport in Saccharo-
myces cerevisiae is mediated by MTR10, a yeast orthologue of TNPO3/
Transportin-SR2 which has been implicated in HIV nuclear import [14].
Association of tRNAs with PIC appears to depend on the Gag protein, at
least replacement of HIV gag with gag of MLV blocked incorporation of
tRNA species into the PIC. It remains to be determined whether this
unusual pathway contributes to nuclear import of HIV in natural target
cells.
Historically, MA was the ﬁrst protein implicated in HIV-1 nuclear
import [30,31]. While most of MA in the virion localizes between the
viral core and the envelope, some MA molecules are found in tight
association with the HIV core and the PIC [32,33]. Two NLSs, 26KKKYK
and 110KSKKK, were identiﬁed in MA and shown to contribute to the
nuclear localization of MA and PIC via interaction with importin α
[34–36]. Interestingly, the basic amino acids in the amino-terminal
portion of MA, together with the N-terminal myristoyl moiety, also
function as the membranotropic signal during viral assembly [37,38].
Switch of the MA tropism from membrane during viral assembly to
nucleus during the early steps of infection remains poorly understood
but is accomplished most likely by posttranslational modiﬁcations
such as phosphorylation [39]. Such dual tropism of MA may be a
reason that nuclear import activity of MA has not been detected in
some reports [40,41]. Alternatively, the MA basic domain may function
at a postnuclear import preintegration step, as reported by Mannioui
and colleagues who found that mutation of MA residues Lys26Lys27
impaired viral infection and 2-LTR circle formation but did not reduce
HIV-1 DNA docking to chromatin [42]. Overall, MA, while contributing
to PIC nuclear import, appears to be non-essential as it is likely only one
of several factors regulating this process (see below). This consideration
explains reports showing that the virus with MA deletions was still
capable of replication, albeit with a greatly reduced efﬁciency [43,44].
Nevertheless, NLSs within the MA may provide a good target for
therapeutic approaches aimed at reducing HIV replication.
Vpr is another HIV-derived protein that has been implicated in
nuclear import. Vpr signiﬁcantly stimulates HIV-1 replication, in
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import of the PIC [45–47]. Vpr has been shown to interact with
importin α [48,49] using amino acid residues 17–34 [50], providing a
mechanism for its nuclear localization. The increased activity of Vpr in
macrophages versus CD4+ T cells was initially explained by the
nondividing state of the former, but in view of the requirement for
nuclear import in both cell types it appears more likely that the PIC
nuclear import pathway in macrophages is different from that in T
cells and needs Vpr. Such ﬂexibility of nuclear import pathways is
consistent with a recent report showing that HIV-1 can use different
nucleoporins and importins for PIC import [16]. Similar toMA, the role
of Vpr is not strictly essential, as viruses lacking Vpr can still replicate
in macrophages, albeit with reduced efﬁciency [46]. The importin-
interacting domain of Vpr presents another target for potential
therapeutic interventions (see below).
A role for IN in HIV-1 nuclear import was originally proposed by
Gallay and co-workers [51], who demonstrated that IN interacts with
importin α and can target a fusion GST-IN protein into the nucleus of
microinjected cells. They also identiﬁed a basic-type NLS spanning
amino acids 186–189, but this claim was later refuted by Tsurutani
and colleagues [52] who demonstrated that this region is involved in
reverse transcription rather than nuclear import. Amore recent report
[53] identiﬁed an unusual NLS spanning residues 161–173 within the
central core domain of IN. IN is highly karyophilic and has been shown
to interact with different importins using different domains, including
importin α1 via the central core domain [51,53,54], importin α3 via
the C-terminal domain (amino acids 250–270) [55], importin 7 via
two regions, 235WKGPAKLLWKG and 262RRKAK, in the C-terminal
domain [56] and TNPO3/transportin-SR2 via the catalytic core
domain close to its N terminus [14]. These importin-interacting
domains of IN present an attractive target for therapeutic
interventions.
In addition to beingkaryophilic itself, INwas shown to interactwith a
host cell karyophilic protein lens epithelium-derived growth factor/
transcriptional co-activator p75 (LEDGF/p75) [57,58]. LEDGF/p75
proteinmarkedly stimulated HIV-1 IN activity in vitro and was reported
to be associated with functional HIV-1 PICs [59]. The normal cellular
function of LEDGF/p75 is still poorly understood, but appears to involve
chromatin tethering of various cellular proteins; a similar function was
proposed for LEDGF/p75 in HIV replication [60]. Interestingly, despite
the presence of a canonical basic-type NLS responsible for nuclear
localization of LEDGF/p75, disruption of this NLS did not abolish
chromatin association of ectopically expressed IN and LEDGF/p75 [61].
This result suggests that LEDGF/p75, in an NLS-independent manner,
may tether IN to chromatin during mitosis and prevent nuclear
exclusionof this complexafter completionofmitosis. This interpretation
does not negate the possibility that NLS of LEDGF/p75may facilitate the
nuclear import of HIV-1 PIC [62], although solid experimental support
for such prospect is lacking. Interaction between IN and LEDGF/p75 is
determined by Trp131/132 and residues 161–170 of the HIV-1 IN
[63,64]. These regions of IN present another target for potential
interventions.
Recent reports suggested that HIV-1 nuclear import is regulated by
the capsid protein CA p24 [16,26,65]. Indeed, mutations in CA
changed the importins and nucleoporins used for PIC nuclear import,
and C-terminally truncated cleavage and polyadenylation factor 6
(CPSF6-358) bound CA and inhibited HIV-1 nuclear import [16].
However, no interaction between CA and importins or nucleoporins
has been reported, suggesting that the role of CA may simply reﬂect
dependence of the PIC nuclear import on uncoating [66]. CA
associated with the incompletely uncoated PIC may alter accessibility
of NLSs to importins and/or interaction between the PIC and
nucleoporins (Fig. 1), and by targeting CA CPSF6-358 may affect
uncoating similar to the effect of TRIM5α. Blocking uncoating of HIV-1
by targeting CA may be another approach to indirectly inhibit HIV
nuclear import. A similar consideration applies to another factorassociated with HIV-1 nuclear import, the HIV-1 DNA Flap. This
structure formed during HIV-1 reverse transcription has been
implicated in HIV-1 nuclear import [67]. The mechanism of DNA
Flap activity is most likely associated with facilitation of PIC uncoating
at the nuclear pore [68]. Another possibility is that Flap provides a
proper structure to the PIC allowing accurate exposure of the NLSs.
Again, drugs targeting Flap may inhibit PIC nuclear import by
affecting uncoating or disturbing the PIC conformation. A model
presenting the currently known factors playing role in HIV-1 PIC
nuclear import is shown in Fig. 1.
In addition to nuclear import of PIC, successful HIV replication also
depends on nuclear import of regulatory proteins Tat and Rev. Tat and
Rev possess arginine-rich NLSs (49RKKRRQRRR57 in Tat and
35RQARRNRRRRWR46 in Rev), which, unlike most basic-type NLSs,
interact with importin β but not with importin α [69]. Drugs
inhibiting interaction between the HIV-1 regulatory proteins and
importin β, presumably by targeting the NLS sequences, are expected
to curtail viral replication.
3. Peptides as a tool to inhibit nuclear import
The process of HIV-1 nuclear import depends on protein–protein
interactions between the PIC components or individual HIV-1
proteins and the cellular nuclear import factors. In many cases,
the domains responsible for these interactions have been charac-
terized (see above). Although some small molecules have been
discovered that can modulate such interactions (see below), the
design of these agents purely from the knowledge of the details of a
given protein–protein interaction, or through screening, remains
highly difﬁcult [70]. Therefore, using peptides derived from either
protein binding partner directly, or after modiﬁcation to improve
afﬁnity and physicochemical properties, continues to be very at-
tractive and resulted in obtaining peptides that can be used to
interfere with protein–protein interactions as well as to obtain
antiviral drugs [71].
Short peptides have a low metabolic stability since linear peptides
are rapidly degraded by intracellular proteolytic activities [72,73].
Structuralmodiﬁcations suchascyclizationhavebeen shown to increase
metabolic stability by making the modiﬁed peptide un-available to
intracellular proteolysis [74]. Side chain to side chain cyclization (SC)
utilizes functional groups like amine, carboxylic acid or thiol, that
naturally exist on the side chains or at the amino or carboxy ends of the
peptide, to form the cyclization through amide or disulﬁde bonds.
Another type of cyclization is the backbone cyclization (BC) that is
preformed by a covalent interconnection of two backbone amides by
artiﬁcial spacer. This strategy signiﬁcantly increases metabolic stability
of the resulted BC peptides [75,76]. Below, we provide a short overview
of theuseof synthetic peptides to inhibit nuclear import of theHIV-1 PIC
and its karyophilic proteins.
There are two possible mechanisms by which peptides can
inhibit NLS-dependent nuclear import: they can either speciﬁcally
interact with the NLS domain of a karyophilic protein masking this
domain and thus preventing its interaction with the appropriate
importin, or they can mimic the domain competing with the NLS-
carrying protein for interaction with importin (Fig. 2). So far, most
nuclear import-inhibiting peptides were designed to function
through the latter mechanism. Peptides derived from SV40 large
T-antigen NLS, which is similar to the NLS of MA and mediates
interaction with importin α, were shown to inhibit nuclear import
of the HIV-1 in CD4+ MT4 cells [77]. Furthermore, screening of the
library of BC peptides bearing the NLS of the MA protein identiﬁed
a BC peptide, designated as BCvir, which inhibited infection of
HIV-1 [78,79].
One of importins shown to interact with HIV-1 IN is importin α
[51,80], so peptides mimicking importin α-interacting NLS on IN were
expected to inhibit HIV-1 infection. This assumption was conﬁrmed by
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Fig. 1. Nuclear import of the HIV-1 PIC. CA protein covers PIC NLSs preventing their interaction with importins. Partial uncoating in the perinuclear area frees some NLSs. Availability
of a particular NLS determines binding of an importin (one or several). The ﬁgure shows PICs binding only one of importins (importin α/β, importin 7, or TNPO3). The importins,
probably via interaction with an importin-speciﬁc nucleoporin, target the PIC to the nuclear pore complex and into the nucleus.
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as NLS–IN [54,81]. Both a cell-permeable peptide bearing the SV40 NLS
and the NLS–IN peptide inhibited nuclear accumulation of IN in
transfected cells and integration of viral cDNA as well as HIV-1
replication in infected cells [81]. As expected, both peptides disrupted
the IN–importin α complex. A similar inhibitory effect was observed
with IN-derived peptide inhibiting IN-TNPO3 interaction (unpublished
observation), consistent with proposed ﬂexible use of nuclear import
pathways by HIV-1 PIC [16].
The cellular protein LEDGF/p75, a binding partner of IN, interacts
with IN primarily through a domain termed the integrase binding
domain (IBD) [82]. Based on the crystal structure and solution structure
analysis of the complex between the LEDGF/p75 IBD and a dimer of the
IN catalytic core domain it can be inferred that residues 361–370 of theIBD interact with the putative IN-NLS (residues 161–173) [83,84].
Support for this view comes from results showing that interaction
between anonkaryophilic version of LEDGF/p75,mutated at its NLS, and
IN blocked nuclear import of the IN [62]. Therefore, a peptide bearing
residues 361–370 of LEDGF/p75was a good candidate as an inhibitor of
INNLS. This notionwas tested byHayouka et al. who demonstrated that
a cell-permeable peptide bearing LEDGF/p75 residues 361–370 inhibits
HIV-1 replication and infection of cultured cells [85,86]. The LEDGF/p75
361–370 peptide may function as an “anti IN-NLS” (Fig. 2), at the same
time preventing interaction of IN with LEDGF/p75 through direct
competition with IBD. Interestingly, the LEDGF/p75-derived peptide
was found to interact also with the NLS sequence of the HIV-1 Rev
protein, but this interaction did not lead to inhibition of the Rev nuclear
import [87].
Fig. 2. Peptides targeting NLS of IN. NLS bearing peptides—such as NLS-IN—compete
with IN for binding to nuclear import receptor (like importin α) and thus block nuclear
import. On the other hand, anti-NLS peptides—such as LEDGF 361–370—bind the NLS of
the karyophilic protein (IN) thus preventing its binding to the nuclear import receptor
(importin α). See text for details.
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has been reported [87,88]. Surprisingly, this interaction inhibited IN
nuclear import [89]. Two Rev-derived peptides, comprising Rev
residues 13–23 and 53–67, were found to speciﬁcally interact with
IN and to promote dissociation of the Rev-IN complex in HIV-infected
cells, supposedly via competition with Rev for binding to IN [87,88]
(Fig. 3). Binding to IN of both peptides blocked nuclear import of the
viral IN and inhibited viral replication ([88–91] and Fig. 3). Interest-
ingly, in contrast to the SV40 and NLS–IN peptides, the Rev-derived
peptides did not disrupt the intracellular IN-importin α complex in
virus-infected cells, but caused dissociation of the IN-TNPO3 complex
(A.L., unpublished observation). In addition, the peptides promoted a
shift in the oligomerization state of IN to predominantly tetrameric
form [92]. It remains to be determined whether inhibition of the IN
nuclear import by these peptides is related to their ability to disrupt
the IN-TNPO3 interaction or to promote IN tetramerization. A similar
nuclear import inhibitory effect and promotion of IN tetramerizationFig. 3. Peptides that disrupt Rev–IN interaction. Rev derived peptides (Rev 13–23 and
Rev 53–67) promote dissociation of the Rev–IN complex allowing nuclear import of Rev
oligomers while shifting the IN oligomeric state to tetramer and consequently blocking
its nuclear import. On the other hand, the INr peptides (INr-1 and INr-2), which also
dissociate the Rev–IN complex, allow nuclear import of IN but block Rev nuclear import,
probably by preventing Rev from forming the oligomeric state required for its nuclear
import. See text for details.was observed with another IN interacting peptide selected from a
peptide library using a yeast 2 hybrid (Y2H) screen [90,91].
Interaction between IN and Rev implies a possibility that IN-
derived peptides may be used to block nuclear import of Rev. To
identify the IN domains responsible for interaction with Rev,
screening of an IN-derived peptide library was performed and
revealed two speciﬁc peptides bearing IN residues 66–80 and 118–
128 (designated INr-1 and INr-2, respectively [93]). Binding of the INr
peptides to Rev in HIV-infected cells disrupted the Rev-IN complex,
similar to the Rev-derived peptides, and thus released the IN from the
Rev inhibitory effect [93,94] (Fig. 3). At the same time, the INr
peptides blocked Rev nuclear import [89]. An ELISA based screening
assay indicated that the INr peptides interact with the oligomerization
domains of the Rev protein [93,95,96] and thus may inhibit Rev
nuclear import by blocking Rev oligomerization required for this step
[97].
Tat is translocated into nuclei of infected cells by arginine rich
motif (ARM) sequences interacting with importin β [69]. Import of
Tat-NLS–BSA conjugate into nuclei of permeabilized cells was
inhibited by several BC peptides bearing the Tat ARM but not—as
expected—by a peptide containing the SV40 NLS [98].
Taken together, the studies described above provide a strong
rationale for further development of peptide-based inhibitors of HIV-1
nuclear import.
4. Small molecular weight inhibitors of HIV-1 nuclear import
MA was the ﬁrst HIV-1 protein implicated in PIC nuclear import,
and theﬁrst efforts to identify inhibitors of HIV-1 nuclear translocation
focused on MA NLS. We approached this goal by looking for
compounds that could neutralize the positive charge on the basic
typeNLS ofMA. Theﬁrst such compoundwas ITI-002 {2-amino-4-(3,5,
diacetylphenyl)-amino-1,6-dimethyl pyrimidine}, which reduced
HIV-1 nuclear import and inhibited viral replication [99,100].
Biochemical analysis showed that ITI-002 associated with HIV-1 MA
protein via the carbonyl residues on the phenol ring of the compound
by forming Schiff base adducts with lysine residues, likely in the ﬁrst
NLS of MA [101]. Such mechanism suggests that the compound may
interact with all lysine-rich sequences and thus may be very toxic.
However, this was not the case. The reason for the ITI-002 speciﬁcity
for MA lies in the initial interaction between the pyrimidine side chain
of ITI-002 and the HIV-1 RT, which is required for accumulation of the
drug in the PIC and shifting the Schiff reaction towards the adducts
[102]. The interactionwith RT appears to be outside the enzyme active
site since generation of the full-length nascent viral cDNA was not
affected by the drug. This interaction with RT is critical for activity of
ITI-002, as the drug did not inhibit nuclear import of model substrates
carrying basic-type NLS, and modiﬁed drugs unable to bind RT did not
inhibit HIV-1 replication [102]. It is likely that interaction with RT is
required to create high concentration of the drug in the vicinity of MA
NLS, thus shifting the equilibrium of the reaction towards Schiff base
formation. This interesting property of arylene bis(methyl ketone)
compounds explains their low toxicity and high speciﬁcity. ITI-002
inhibited HIV-1 replication in both macrophages and CD4+ T cells, as
well as in ex vivo cultured lymphoid tissue [100]. Given that MA
appears to be only one of several interchangeable factors mediating
HIV-1 nuclear import, such potent inhibition of HIV-1 replication by
MANLS-targeting compoundcame as a surprise. A likely explanation is
that ITI-002 may inhibit also later (postintegration) steps of viral
replication which are dependent on the basic region of MA. One such
step is viral assembly, as the basic region of MA within the Gag
precursor is a key membranotropic signal [103].
Another class of compounds targeting the MANLS, oxadiazols, was
selected using computer-aided drug design (CADD) by modeling a
250,000 compound library on the crystal structure of the HIV-1 MA
[104]. These compounds were predicted to bind to MA within a
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orientation of the tyrosine residue (amino acid no. 29). ITI-367 [3-(2-
methoxyphenyl)-4-[3-(triﬂuoromethyl)phenyl-1,2,4-oxadiazol-5
(4H)-one], a lead compound from this group, inhibited the binding of
the PIC to importin α, PIC nuclear import, and HIV replication in
macrophages and CD4+ T cells [104]. Importantly, ITI-367 demon-
strated at least an additive inhibitory effect when combined in vitro
with nucleoside reverse transcriptase inhibitors (AZT, d4T), non-
nucleoside reverse transcriptase inhibitors (efavirenz), or protease
inhibitors (saquinavir, nelﬁnavir). Following culture of HIV-infected
cells in the presence of increasing concentrations of ITI-367, a drug-
resistant mutant was produced. Surprisingly, mutations identiﬁed in
this virus localized to the cytoplasmic domain of gp41, but not to MA
(unpublished results). This result suggests that the main step of HIV
replication affected by ITI-367 is the step of virus assembly, rather
than PIC nuclear import. Indeed, interaction between the MA-
corresponding part of Gag and the cytoplasmic tail of gp41 is critical
for production of infectious virions [105–107], and the L30E mutation
located within the MA NLS impairs this interaction [106]. This result,
consistent with ﬂexible use of nuclear import pathways by HIV-1 PIC,
underscores attractiveness of the MA protein as a target for
therapeutic interventions.
Vpr is another HIV-1 protein implicated in PIC nuclear import.
Although a number of mechanisms were proposed to explain nuclear
localization of Vpr [108], association of Vpr with importin α has been
reported by several independent groups [48–50,109]. Searching for
compounds that can speciﬁcally inhibit the interaction between
importin α and amino acids 17–34 of Vpr, shown to be indispensable
for nuclear import of Vpr and for HIV-1 replication inmacrophages [50],
identiﬁed hematoxylin [110]. Hematoxylin inhibited speciﬁc binding of
Vpr to importin α in a dose-dependent manner; it also inhibited HIV-1
replication in macrophages and nuclear import of HIV-1 PIC at
concentrations 20–40 μM [110]. Importantly, hematoxylin did not
impair the ability of Vpr to induce G2 cell cycle arrest, suggesting a
speciﬁc effect onVpr-mediatednuclear import. Surprisingly, the authors
reported that the drug did not inhibit HIV-1 replication in PBMC. This
result may reﬂect different requirements for PIC nuclear import in
different cell types; nuclear import in PBMC may not require Vpr.
Styrylquinolines have been recognized as potent HIV-1 IN
inhibitors that block HIV-1 replication in cell-based assays [111].
This activity may be determined, at least in part, by a speciﬁc
inhibition of IN nuclear import [112]. It should be noted here that the
effect on IN nuclear import was only seen at relatively high
concentrations of the drug (30 μM). However, nuclear import of
karyophiles carrying basic-type NLSs similar to the NLS of SV40 T
antigen was not affected by these concentrations of styrylquinolines,
suggesting that the drug inhibited IN interaction with importins that
are not involved in transport of SV40 T antigen-type NLSs, e.g.,
importin 7 or TNPO3. It seems likely that binding of the compounds to
IN impair both the integration activity and nuclear import of the
protein. These functions appear to be regulated by adjacent or even
overlapping sites on IN.
5. Conclusions
Development of HIV-speciﬁc nuclear import inhibitors critically
depends on the progress of basic research aimed at understanding the
molecularmechanisms of this process. This ﬁeld is rapidly evolving. At
present, it appears that nuclear import of HIV-1 PIC is a highly ﬂexible
process involving a number of interchangeable pathways. It is
possible that these pathways are speciﬁc for certain cell types (e.g.,
macrophages or CD4+ T cells). Alternatively, several pathwaysmay be
used by the virus in each cell type, with selection depending on a cell
status, such as activation or cell cycle progression. The cell status
parameters may inﬂuence HIV nuclear import through an effect on
viral uncoating: accelerated or delayed uncoating may change theimport pathway used by the virus through altering accessibility of
NLSs on PIC proteins. Therefore, the optimal approach to designing a
universal inhibitor of HIV-1 PIC nuclear import is to target a step in
viral replication preceding the nuclear import pathway bifurcation
(Fig. 1). A good candidate for this approach is the step of HIV
uncoating regulated by the CA protein. Although uncoating is not
formally a step of nuclear import, CA appears to determine the nuclear
import pathway used by the virus [16], so drugs blocking ormodifying
uncoating may also block viral nuclear import. Targeting nuclear
import of individual viral proteins, Tat and Rev, may be an easier task,
although such approach has the danger of allowing viral integration.
It can be expected that new ﬁndings will provide the basis for the
design of compounds targeting not only viral proteins, but also their
cellular counterparts, such as importins and nucleoporins. While
targeting cellular proteins with drugs carries a danger of cytotoxicity,
some compromises may be worked out. For example, multiple
isoforms of proteins involved in nuclear import are expressed in
eukaryotic cells [113]. These isoforms are speciﬁc for transporting
certain substrates, and it is possible that isoforms may be identiﬁed
that are essential for survival of the virus but not of the host cell.
A major concernwith any new anti-HIV therapy is the development
of drug-resistant mutants. Future studies will likely identify mutations
that provide some resistance to nuclear import inhibitors. It would be
interesting to ﬁnd out whether resistant virus can emerge when drugs
targeting several viral nuclear import factors are used simultaneously.
Given that viral proteins need to interact with very conserved cellular
nuclear import factors, it can be expected that the ﬁtness of such
resistant virus will be greatly compromised. This would be good news
for anti-HIV therapy, as unﬁt HIVmay bewell controlled by the immune
system and other drugs in the HAART cocktail.
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